StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

NASDAQ EGRX opened at $3.73 on Tuesday. Eagle Pharmaceuticals has a 12 month low of $3.50 and a 12 month high of $23.52. The company has a market capitalization of $48.44 million, a price-to-earnings ratio of 3.16 and a beta of 0.46. The company’s fifty day moving average price is $4.79 and its two-hundred day moving average price is $5.74.

Institutional Trading of Eagle Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Headlands Technologies LLC raised its holdings in shares of Eagle Pharmaceuticals by 263.4% during the third quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 1,686 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Eagle Pharmaceuticals by 623.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock worth $36,000 after purchasing an additional 5,896 shares during the period. Strs Ohio acquired a new stake in shares of Eagle Pharmaceuticals during the third quarter worth $145,000. DGS Capital Management LLC acquired a new stake in shares of Eagle Pharmaceuticals during the fourth quarter worth $60,000. Finally, Connors Investor Services Inc. raised its holdings in shares of Eagle Pharmaceuticals by 24.8% during the third quarter. Connors Investor Services Inc. now owns 12,566 shares of the specialty pharmaceutical company’s stock worth $198,000 after purchasing an additional 2,500 shares during the period. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.